title: Radiosurgery to the postoperative surgical cavity: who needs evidence?
abstract: There is a growing interest in adjuvant radiosurgery after resection of hematogenous brain metastases. This is exemplified by the approximately 1000 cases reported in mainly retrospective series. These cases fall into four paradigms: adjuvant radiosurgery as an alternative to whole-brain radiotherapy (WBRT), radiosurgery neoadjuvant to the surgical resection, radiosurgery as an intensification of adjuvant WBRT, and adjuvant radiosurgery for patients having failed prior WBRT. These procedures seem well tolerated, with an approximate 5% risk of radiation necrosis. Although crude local control rates for each strategy seem improved over surgery alone, multiple biases make comparisons with standard WBRT difficult without prospective data. Because evidence lags behind clinical practice, an upcoming intergroup trial will aim to clarify the value of the most common tumor bed radiosurgery strategy by randomizing oligometastatic patients between adjuvant WBRT and adjuvant radiosurgery.
authors.affiliation: Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC, Canada. david.roberge@mcgill.ca
authors.forename: David
authors.initials: D
authors.lastname: Roberge
authors.forename: Ian
authors.initials: I
authors.lastname: Parney
authors.forename: Paul D
authors.initials: PD
authors.lastname: Brown
mesh_terms: D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011184:Postoperative Period; D016634:Radiosurgery / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D047368:Tumor Burden